Update on GPIIb/IIIa antagonists

Bibliography

• DOGNE JM, LEVAL XD X, BENOIT P et al.: Recent advances in antiplatelet agents. Curr. Med. Chem. (2002) 9:577–589.
   PubMedGoogle Scholar
• ••Review of antiplatelet agents.
   Google Scholar
• BENOIT P, DOGNE JM: Platelet ADP receptors and their antagonists. Mini. Rev Med. Chem. (2003) 3:145–148.
   PubMedGoogle Scholar
• PHILLIPS DR, JENNINGS LK, EDWARDS HH: Identification of membrane proteins mediating the interaction of human platelets. Cell. Biol. (1980) 86:77–86.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, BYZOVA TV, PLOW EF: Platelet GPIIb-IIIa blockers. Lancet (1999) 353:227–231.
   PubMed Web of Science ®Google Scholar
• •Good review of GPIIWIlla antagonists.
   Google Scholar
• WAGNER CL, MASCELLI MA, NEBLOCK DS et al.: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:907–914.
   PubMed Web of Science ®Google Scholar
• FRENETTE PS, WAGNER DD: Adhesion molecules-Part II: blood vessels and blood cells. N Engl. J. Med. (1996) 335:43–45.
   PubMed Web of Science ®Google Scholar
• ••For readers interested in adhesion moleculesImplicated in blood disorders.
   Google Scholar
• FRENETTE PS, WAGNER DD: Adhesion molecules-Part 1. N Engl. J. Med. (1996) 334:1526–1529.
   PubMed Web of Science ®Google Scholar
• ••For readers interested in adhesion molecules.
   Google Scholar
• COLLER BS, PEERSCHKE El, SCUDDER LE, SULLIVAN CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or Ma. J. aim Invest. (1983) 72:325–338.
   PubMed Web of Science ®Google Scholar
• •Discovery and characterisation of abciximab.
   Google Scholar
• MOSESSON MW, SIEBENLIST KR, MEH DA: The structure and biological20.features of fibrinogen and fibrin. Ann. NY Acad. Sci. (2001) 936:11–30.
   PubMed Web of Science ®Google Scholar
• COLLER BS: A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. Clin. Invest. (1985) 76:101–108.
   Google Scholar
• COLLER BS, SCUDDER LE, BEER J et al: Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. NY Acad. Sci. (1991) 614:193–213.
   PubMed Web of Science ®Google Scholar
• CHARO IF, BEKEART LS, PHILLIPS DR:Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. I. Biol. Chem. (1987) 262:9935–9938.
   Google Scholar
• ALTIERI DC, EDGINGTON TS: A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J. Immunot. (1988) 141:2656–2660.
   Google Scholar
• NO AUTHORS LISTED: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl. J. Med. (1997) 336:1689–1696.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl. J. Med. (1994) 330:956–961.
   PubMedGoogle Scholar
• TCHENG JE, O'SHEA JC: Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. Expert. Opin. Investig. Drugs. (1999) 8:1893–1905.
   PubMedGoogle Scholar
• SCARBOROUGH RIVI, ROSE JW, HSU MA et al: Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus M barbouri. J. Biol. Chem. (1991) 266:9359–9362.
   PubMedGoogle Scholar
• •Discovery of eptifibatide.
   Google Scholar
• SCARBOROUGH RIVI, NAUGHTON MA, TENG Wet al.: Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. (1993) 268:1066–1073.
   Google Scholar
• AUTHORS LISTED: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl. J. Med. (1998) 339:436-443. Clinical study with eptifibatide.
   Google Scholar
• NO AUTHORS LISTED: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet (1997) 349:1422–1428.
   Google Scholar
• HARTMAN GD, EGBERTSON MS, HALCZENKO W et al: Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. (1992) 35:4640–4642.
   Google Scholar
• NO AUTHORS LISTED: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. N Engl. J. Med. (1998) 338:1498–1505.
   Google Scholar
• •Clinical study evaluating tirofiban.
   Google Scholar
• NO AUTHORS LISTED: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N. Engl. J. Med. (1998) 338:1488–1497.
   Google Scholar
• CO MS, YANO S, HSU RK et al: A humanized antibody specific for the platelet integrin gpIIb/IIIa. Immunol (1994) 152:2968–2976.
   Google Scholar
• KAKU S, KAWASAKI T, HISAMICHI N et al.: Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb. Haemost. (1996) 75:679–684.
   PubMedGoogle Scholar
• SUZUKI K, SAKAI Y, HISAMICHI N eta].: Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur. Pharmacol (1997) 336:169–176.
   Google Scholar
• HARDER S, KIRCHMAIER CM, KRZYWANEK HJ et al: Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation (1999) 100:1175–1181.
   PubMedGoogle Scholar
• KAMATH S, LIP GY: YM-337. Yamanouchi. CUM Opin. Invectig Drugs. (2001) 2:1093–1096.
   PubMedGoogle Scholar
• ALIG L, EDENHOFER A, HAD VARY P eta].: Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. (1992) 35:4393–4407.
   Google Scholar
• THEROUX P, KOUZ S, ROY L et al: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian lamifiban study. Circulation (1996) 94:899–905.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation (1998) 97:2386-2395. 1185 Expert Opin. Ther. Patents (2003) 13(8)
   Google Scholar
• MOLITERNO DJ: Patient-specific dosingof IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B international steering committee. Am. Heart. J. (2000) 139:563–566.
   PubMed Web of Science ®Google Scholar
• GLOBAL ORGANIZATION NETWORK (PARAGON)-B INVESTIGATORS: Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation (2002) 105:316–321.
   PubMedGoogle Scholar
• WELLER T, AUG L, BERESINI M et al: Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Med. Chem. (1996) 39:3139–3147.
   PubMed Web of Science ®Google Scholar
• REFINO CJ, MODI NB, BULLENS S et al.: Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GPIIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb. Haemost. (1998) 79:169–176.
   PubMed Web of Science ®Google Scholar
• THE SYMPHONY INVESTIGATORS: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet (2000) 355:337–345.
   Google Scholar
• SECOND SYMPHONY INVESTIGATORS: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation (2001) 103:1727–1733.
   PubMed Web of Science ®Google Scholar
• O'NEILL WW, SERRUYS P, KNUDTSON M et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl. Med. (2000) 342:1316–1324.
   Google Scholar
• OGAWA T, SUGIDACHI A, NAGANUMA H, ASAI F: Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs. Thromb. Res. (2000) 97:307–315.
   PubMedGoogle Scholar
• ANDERS R, KLEIMAN J, NICHOLSON N, WAZOWICZ B, BURNS D: Xemilofiban/orbofiban: insight into drug development. Cardiovasc. Drug. Rev (2001) 19:116–132.
   PubMedGoogle Scholar
• CANNON CP, MCCABE CH, WILCOX RG et al: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation (2000) 102:149–156.
   PubMed Web of Science ®Google Scholar
• LIU F, CRAFT RM, MORRIS SA, CARROLL RC: Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert. Opin. Investig. Drugs (2000) 9:2673–2687.
   PubMed Web of Science ®Google Scholar
• •Recent review on lotrafiban.
   Google Scholar
• TOPOL EJ, EASTON JD, AMARENCO P et al.: Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am. Heart. (2000) 139:927–933.
   PubMed Web of Science ®Google Scholar
• SORELLE R: SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor. Circulation (2001) 103:E9001–E9002.
   Google Scholar
• CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation (2001) 103:201–206.
   PubMed Web of Science ®Google Scholar
• ADDERLEY SR, FITZGERALD DJ: Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J. Biol. Chem. (2000) 275:5760–5766.
   PubMedGoogle Scholar
• ERHARDT JA, OHLSTEIN EH, TOOMEY JR et al: Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb. Res. (2001) 103:143–148.
   PubMedGoogle Scholar
• PETER K, SCHWARZ M, YLANNE J et al.: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (amI33) inhibitors. Blood (1998) 92:3240–3249.
   PubMed Web of Science ®Google Scholar
• ••Interesting publication on the clinicalinefficacy of oral GPIIb/IIIa inhibitors.
   Google Scholar
• COX D, SMITH R, QUINN M et al.: Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J. Am. Coll. Cardiol (2000) 36:1514–1519.
   PubMed Web of Science ®Google Scholar
• HOLMES MB, SOBEL BE, CANNON CP, SCHNEIDER DJ: Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction. Am. J. Cardiol (2000) 85:491-493, A410.
   Google Scholar
• MOUSA SA, FORSYTHE M, LORELEI W et al.: Novel non-peptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron. Artery Dis. (1996) 7:767–774.
   PubMed Web of Science ®Google Scholar
• XUE CB, WITYAK J, SIELECKI TM et al: Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists. Med. Chem. (1997) 40:2064–2084.
   Google Scholar
• MOUSA SA, KAPIL R, MU DX: Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2535–2541.
   PubMed Web of Science ®Google Scholar
• PIENIASZEK HJ Jr, SY SK, EBLING W et al.: Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Pharmacol (2002) 42:738–753.
   Google Scholar
• MOUSA SA, FORSYTHE M, BOZARTH J et al.: XV454, a novel non-peptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet a1j433-binding kinetics to c7E3. Cardiovasc. Pharmacol (1998) 32:736–744.
   PubMedGoogle Scholar
• MOUSA SA, BOZARTH JM, NAIK UP, SLEE A: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. BE Pharmacia]. (2001) 133:331–336.
   PubMed Web of Science ®Google Scholar
• MULLER TH, WEISENBERGER H, BRICKL R et al: Profound and sustained inhibition of platelet aggregation by fradafiban, a non-peptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation (1997) 96:1130–1138.
   PubMed Web of Science ®Google Scholar
• AKKERHUIS KM, NEUHAUS KL, WILCOX RG et al: Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a Phase II study. Eur. Heart. J. (2000) 21:2042–2055.
   PubMedGoogle Scholar
• HOEKSTRA WJ, BEAVERS MP, ANDRADE-GORDON P et al: Design and evaluation of non-peptide fibrinogen 7-chain based GPIIb/IIIa antagonists. J. Med. Chem. (1995) 38:1582–1592.
   PubMedGoogle Scholar
• HOEKSTRA WJ, MARYANOFF BE, DAMIANO BP et al: Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. Med. Chem. (1999) 42:5254–5265.
   Google Scholar
• DAMIANO BP, MITCHELL JA, GIARDINO E et al.: Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb. Res. (2001) 104:113–126.
   PubMed Web of Science ®Google Scholar
• VAN HECKEN A, DEPRE M, WYNANTS K et al.: Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug. Metabol Drug. Interact. (1998) 14:193–205.
   PubMedGoogle Scholar
• MEIBOHM B, NEUGEBAUER R, BUHRING KU, SCHULTE M, KOVAR A: J. Chi]. Pharmacol (1999) 39:978.
   Google Scholar
• HUANG J, REBELLO SS, ROSENBERG LA et al: Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Eur. Pharmacol (1999) 366:203–213.
   PubMedGoogle Scholar
• REBELLO SS, HUANG J, SHIU WJ et al: Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. J. Cardiovasc. Pharmacol (1998) 32:485–494.
   PubMedGoogle Scholar
• REBELLO SS, HUANG J, SAITO K, LUCCHESI BR: In vivo efficacy of SM-20302, a GPIIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler. Thromb. Vase. Biol. (1998) 18:954–960.
   PubMedGoogle Scholar
• HORISAWA S, KANEKO M, SAKURAMA T: SM-20302, a non-peptide GPIIb/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed hemorrhage model in mice. Thromb. Haemost. (1999) 82:1743–1748.
   PubMedGoogle Scholar
• HORISAWA S, KANEKO M, IKEDA Y, UEKI Y, SAKURAMA T: Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs. Thromb. Res. (1999) 94:227–234.
   PubMedGoogle Scholar
• HORISAWA S, KANEKO M, SAKURAMA T: Protective effects of SM-20302, an orally active GPIIb/IIIa antagonist, in an ADP/epinephrine-induced guinea pig model of transient cerebral ischemia. Thromb. Res. (2001) 101:119–126.
   PubMedGoogle Scholar
• SMALLHEER JM, OLSON RE, WEXLER RR: Antiplatelet therapies. Ann. Rep. Med. Chem. (2000) 35:103–122.
   Web of Science ®Google Scholar
• ••A very complete review of antiplatelettherapies.
   Google Scholar
• KAWAMURA M, TSUJI N, MORIYA N, TERASHITA Z: Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb. Res. (1997) 86:275–285.
   PubMedGoogle Scholar
• KAWAMURA M, IMURA Y, MORIYA N et al: Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin El and argatroban. Pharmacol Exp. Ther. (1996) 277:502–510.
   PubMedGoogle Scholar
• STILZ HU, GUBA W, JABLONKA B et al:Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. I Med. Chem. (2001) 44:1158–1176.
   PubMed Web of Science ®Google Scholar
• OKUMURA K, SHIMAZAKI T, AOKI Y et al.: New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template. J. Med. Chem. (1998) 41:4036–4052.
   PubMedGoogle Scholar
• BANNO H, KAWAZURA H, YUTAKA T et al.: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist. Eur..I. Pharmacol (1999) 367:275–282.
   PubMedGoogle Scholar
• BADORC A, BORDES MF, DE COINTET P et al: New orally active non-peptide fibrinogen receptor (GPIIb-IIIa) antagonists: identification of ethyl 3- [N- [4-[4- [amino Rethoxycarbonyl) imincd methyl] p henyll -1, 3 -thiazol 2-y1] -N-[1- RethoxycarbonyOmethylIpip erid-4-amino[propionate (SR 121787) as a potent and long-acting antithrombotic agent. Med. Chem. (1997) 40:3393–3401.
   Web of Science ®Google Scholar
• HOFFMANN P, BERNAT A, SAVI P, HERBERT JM: Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. J. PharmacolExp. Ther. (1998) 286:670–675.
   PubMedGoogle Scholar
• SAVI P, BADORC A, LALE A et al.: SR 121787, a new orally active fibrinogen receptor antagonist. Thromb. Haemost. (1998) 80:469–476.
   PubMedGoogle Scholar
• BERNAT A, SAVI P, LALE A, HOFFMANN P, HERBERT JM: The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent Factor Xa inhibition without an increase in the bleeding risk in the rabbit. ./. Cardiovasc. Pharmacol (1999) 33:573–579.
   PubMedGoogle Scholar
• HARADA T, KATADA J, TACHIKI A et al.: Development of the new potent non-peptide GPIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique. Bioorg. Med. Chem. Lett. (1997) 7:209–212.
   Google Scholar
• HAYASHI Y, KATADA J, HARADA T et al.: GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure. J. Med. Chem. (1998) 41:2345–2360.
   PubMedGoogle Scholar
• OLSON RE, SIELECKI TM, WITYAK Jet al.: Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. ./. Med. Chem. (1999) 42:1178–1192.
   Google Scholar
• MOUSA SA, OLSON RE, BOZARTH JM et al.: Oral antiplatelet efficacy and specificity of a novel non-peptide platelet GPIIb/IIIa receptor antagonist, DMP 802. Cardiovasc. Pharmacol (1998) 32:169–176.
   PubMedGoogle Scholar
• SIELECKI TM, LIU J, MOUSA SA et al:Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2201–2204.
   PubMed Web of Science ®Google Scholar
• SMYTH MS, ROSE J, MEHROTRA MM et al.: Spirocyclic nonpeptide glycoprotein lib-IIIa antagonists. Part 1: design of potent and specific 3, 9-diazaspiro [5.5]undecanes. Bioorg. Med. Chem. Lett. (2001) 11:1289–1292.
   Google Scholar
• PANDEY A, SEROOGY J, VOLKOTS D et al.: Spirocyclic nonpeptide glycoprotein lib-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes. Bioorg. Med. Chem. Lett. (2001) 11:1293–1296.
   Google Scholar
• MEHROTRA MM, HEATH JA, ROSE JW et al.: Spirocyclic non-peptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro [4.5]decanes. Bioorg. Med. Chem. Lett. (2002) 12:1103–1107.
   Google Scholar
• LIVERTON NJ, ARMSTRONG DJ, CLAREMON DA etaL: Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett. (1998) 8:483–486.
   PubMed Web of Science ®Google Scholar
• ROBARGE KD, DINA MS, SOMERS TC et al.: Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorg. Med. Chem. (1998) 6:2345–2381.
   PubMedGoogle Scholar
• BLACKBURN BK, LEE A, BAIER M et al:From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. J. Med. Chem. (1997) 40:717–729.
   Google Scholar
• ADDICKS E, MAZITSCHEK R, GIANNIS A: Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues. Chembiochem. (2002) 3:1078–1088.
   PubMedGoogle Scholar
• EGBERTSON MS, COOK JJ, BEDNAR B et al.: Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene a-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J. Med. Chem. (1999) 42:2409–2421.
   Google Scholar
• FISHER MJ, ARFSTAN AE, GIESE U et al: Fused bicyclic Gly-Asp 13-turn mimics with specific affinity for GPIIb-IIIa. J. Med. Chem. (1999) 42:4875–4889.
   PubMedGoogle Scholar
• FISHER MJ, GIESE U, HARMS CS et al: Fused bicyclic Gly-Asp 13-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere. Bioorg. Med. Chem. Lett. (2000) 10:385–389.
   PubMedGoogle Scholar
• SUGIHARA H, FUKUSHI H, MIYAWAKI T et al: Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3, 4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J. Med. Chem. (1998) 41:489–502.
   Google Scholar
• KITAMURA S, FUKUSHI H, MIYAWAKI T et al: Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives. J. Med. Chem. (2001) 44:2438–2450.
   PubMedGoogle Scholar
• FELDING-HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr. ()pia Cell Biol. (1993) 5:864–868.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of vitronectin.
   Google Scholar
• COLLER BS, CHERESH DA, ASCH E, SELIGSOHN U: Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood (1991) 77:75–83.
   PubMed Web of Science ®Google Scholar
• SRIVATSA SS, FITZPATRICK LA, TSAO PW et al.: Selective aj33 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin 03 and osteopontin expression during neointima formation. Cardiovasc. Res. (1997) 36:408–428.
   PubMed Web of Science ®Google Scholar
• BENNETT JS, CHAN C, VILAIRE G, MOUSA SA, DEGRADO WF: Agonist- activated 03 on platelets and lymphocytes binds to the matrix protein osteopontin. J. Biol. Chem. (1997) 272:8137–8140.
   PubMed Web of Science ®Google Scholar
• REVERTER JC, BEGUIN S, KESSELS H et al.: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'../. Clio. Invest. (1996) 98:863–874.
   Google Scholar
• STOUFFER GA, HU Z, SAJID M et al.: P3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation (1998) 97:907–915.
   PubMed Web of Science ®Google Scholar
• ••Publication on the potential implication of the vitronectin receptor in haemostasis.
   Google Scholar
• HOSHIGA M, ALPERS CE, SMITH LL, GIACHELLI CM, SCHWARTZ SM: a\133 integrin expression in normal and atherosclerotic artery. Circ. Res. (1995) 77:1129–1135.
   PubMed Web of Science ®Google Scholar
• SLEPIAN MJ, MASSIA SP, DEHDASHTI B, FRITZ A, WHITESELL L: 133-integrins rather than 131-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation (1998) 97: 1818-1827.
   Google Scholar
• BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular integrin a.J33 for angiogenesis. Science (1994) 264:569–571.
   Google Scholar
• •Implication of the vitronectin receptor in angiogenesis.
   Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin avi33 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R et al: Anti-integrin a.,433 blocks human breast cancer growth and angiogenesis in human skin. J Chit. Invest. (1995) 96:1815–1822.
   Google Scholar
• VARNER JA, CHERESH DA: Integrins and cancer. Curi: °pia Cell Biol. (1996) 8:724–730.
   PubMed Web of Science ®Google Scholar
• ALI FE, BENNETT DB, CALVO RR et al: Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J Med. Chem. (1994) 37:769–780.
   PubMed Web of Science ®Google Scholar
• WONG A, HWANG SM, MCDEVITT P et al.: Studies on avN/ligand interactions using a PHISK&F-107260 binding assay. Mol Pharmacol (1996) 50:529–537.
   PubMed Web of Science ®Google Scholar